Saul B Freedman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4219795/publications.pdf

Version: 2024-02-01

278 papers

15,358 citations

20759 60 h-index 20900 115 g-index

285 all docs

285 docs citations

times ranked

285

13773 citing authors

#	Article	IF	CITATIONS
1	Risk of Ischemic Stroke in Asymptomatic Atrial Fibrillation Incidentally Detected in Primary Care Compared with Other Clinical Presentations. Thrombosis and Haemostasis, 2022, 122, 277-285.	1.8	33
2	Atrial Fibrillation Detected by Single Time-Point Handheld Electrocardiogram Screening and the Risk of Ischemic Stroke. Thrombosis and Haemostasis, 2022, 122, 286-294.	1.8	26
3	Alcohol binge drinking and delirium cordis. , 2022, 1, 6-7.		O
4	Updated USPSTF Guidelines for Screening for Atrial Fibrillation. JAMA Cardiology, 2022, , .	3.0	1
5	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. Circulation, 2022, 145, 392-409.	1.6	65
6	2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening. Journal of Arrhythmia, 2022, 38, 31-49.	0.5	14
7	Costâ€Effectiveness of Monitoring Patients Postâ€Stroke With Mobile ECG During the Hospital Stay. Journal of the American Heart Association, 2022, 11, e022735.	1.6	4
8	Alcohol consumption in relation to the incidence of atrial fibrillation in an elderly Chinese population Journal of Geriatric Cardiology, 2022, 19, 52-60.	0.2	2
9	Feasible approaches and implementation challenges to atrial fibrillation screening: a qualitative study of stakeholder views in 11 European countries. BMJ Open, 2022, 12, e059156.	0.8	3
10	Screening for atrial fibrillation to prevent stroke: a meta-analysis. European Heart Journal Open, 2022, 2, .	0.9	15
11	Screen-detected atrial fibrillation predicts mortality in elderly subjects. Europace, 2021, 23, 29-38.	0.7	19
12	Next frontier for stroke prevention in atrial fibrillation: ensuring anticoagulant persistence. Heart, 2021, 107, 519-520.	1.2	4
13	Atrial Fibrillation in Indigenous Australians: A Multisite Screening Study Using a Single-Lead ECG Device in Aboriginal Primary Health Settings. Heart Lung and Circulation, 2021, 30, 267-274.	0.2	10
14	Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study. International Journal of Cardiology, 2021, 323, 83-89.	0.8	15
15	World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. Global Heart, 2021, 16, 41.	0.9	39
16	Atrial fibrillation self screening, management and guideline recommended therapy (AF SELF SMART): A protocol for atrial fibrillation self-screening in general practice. IJC Heart and Vasculature, 2021, 32, 100683.	0.6	4
17	Atrial fibrillation prevalence and risk profile from novel community-based screening in Thailand: A prospective multi-centre study. IJC Heart and Vasculature, 2021, 32, 100709.	0.6	7
18	Next frontier in management of atrial fibrillation. Heart, 2021, 107, 767.2-768.	1.2	0

#	Article	IF	CITATIONS
19	Clinical Factors Associated with Atrial Fibrillation Detection on Single-Time Point Screening Using a Hand-Held Single-Lead ECG Device. Journal of Clinical Medicine, 2021, 10, 729.	1.0	30
20	Decoding stroke risk scores in atrial fibrillation: still more work to do. European Heart Journal, 2021, 42, 1486-1488.	1.0	3
21	Response to letter to the editor regarding: "Atrial fibrillation prevalence and risk profile from novel community-based screening in Thailand: A prospective multi-centre study― IJC Heart and Vasculature, 2021, 33, 100752.	0.6	0
22	Screening for Atrial Fibrillation in American Indian Adults in a Tribal Primary Care Clinic. Journal of the American Heart Association, 2021, 10, e020069.	1.6	8
23	Subclinical Atrial Fibrillation and the Risk of Recurrent Ischemic Stroke. Thrombosis and Haemostasis, 2021, 121, 697-699.	1.8	13
24	Searching for atrial fibrillation post-stroke with prolonged monitoring: Do it early, but should we be looking for something else?. IJC Heart and Vasculature, 2021, 34, 100819.	0.6	0
25	Periodontitis induces endothelial dysfunction in mice. Scientific Reports, 2021, 11, 14993.	1.6	9
26	Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening. American Journal of Medicine, 2021, 134, 893-901.e11.	0.6	31
27	Quarterly versus annual ECG screening for atrial fibrillation in older Chinese individuals (AF-CATCH): a prospective, randomised controlled trial. The Lancet Healthy Longevity, 2021, 2, e470-e478.	2.0	6
28	Stroke Risk in Adults With Atrial Fibrillation According to Sex. Heart Lung and Circulation, 2021, 30, 937-938.	0.2	0
29	Population screening for atrial fibrillation to prevent stroke. Lancet, The, 2021, 398, 1463-1465.	6.3	3
30	High-intensity atrial fibrillation screening to prevent stroke. Lancet, The, 2021, 398, 1465-1467.	6.3	5
31	Refined atrial fibrillation screening and cost-effectiveness in the German population. Heart, 2021, , heartjnl-2020-318882.	1.2	5
32	Research Priorities in Atrial Fibrillation Screening. Circulation, 2021, 143, 372-388.	1.6	42
33	The Australian Cardiovascular Alliance (ACvA). European Heart Journal, 2021, 42, 8-10.	1.0	2
34	Incidence of New Onset Atrial Fibrillation After Cardiovascular Surgery in Vietnam: Results From A Novel Screening Strategy. Journal of Atrial Fibrillation, 2021, 14, 20200503.	0.5	0
35	Implementing screening interventions in community pharmacy to promote interprofessional coordination of primary care $\hat{a} \in A$ mixed methods evaluation. Research in Social and Administrative Pharmacy, 2020, 16, 160-167.	1.5	15
36	Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study. Journal of Thrombosis and Thrombolysis, 2020, 49, 606-617.	1.0	13

3

#	Article	IF	Citations
37	High-Throughput, Contact-Free Detection of Atrial Fibrillation From Video With Deep Learning. JAMA Cardiology, 2020, 5, 105.	3.0	65
38	Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices and apps: A survey of health care professionals by AF-SCREEN international collaboration. European Journal of Internal Medicine, 2020, 82, 97-104.	1.0	38
39	Self-monitoring for recurrence of secondary atrial fibrillation following non-cardiac surgery or acute illness: A pilot study. IJC Heart and Vasculature, 2020, 29, 100566.	0.6	O
40	Screening for atrial fibrillation: predicted sensitivity of short, intermittent electrocardiogram recordings in an asymptomatic at-risk population. Europace, 2020, 22, 1781-1787.	0.7	24
41	An Al-ECG algorithm for atrial fibrillation risk: steps towards clinical implementation. Lancet, The, 2020, 396, 236.	6.3	2
42	Detection rate and treatment gap for atrial fibrillation identified through screening in community health centers in China (AF-CATCH): A prospective multicenter study. PLoS Medicine, 2020, 17, e1003146.	3.9	25
43	Atrial fibrillation: villain or bystander in vascular brain injury. European Heart Journal Supplements, 2020, 22, M51-M59.	0.0	20
44	An Al-ECG algorithm for atrial fibrillation risk: steps towards clinical implementation. Lancet, The, 2020, 396, 235-236.	6.3	3
45	Atrial Fibrillation Screen, Management, and Guidelineâ€Recommended Therapy in the Rural Primary Care Setting: A Crossâ€Sectional Study and Costâ€Effectiveness Analysis of eHealth Tools to Support All Stages of Screening. Journal of the American Heart Association, 2020, 9, e017080.	1.6	23
46	Artificial intelligence in health care: preparing for the fifth Industrial Revolution. Medical Journal of Australia, 2020, 213, 253.	0.8	14
47	Incremental yield of ECG screening repeated annually over 4 years in an adult Japanese population without prior atrial fibrillation: a retrospective cohort study. BMJ Open, 2020, 10, e035650.	0.8	9
48	High-Density Lipoprotein (HDL) Inhibits Serum Amyloid A (SAA)-Induced Vascular and Renal Dysfunctions in Apolipoprotein E-Deficient Mice. International Journal of Molecular Sciences, 2020, 21, 1316.	1.8	14
49	Time to develop guidelines for screening and management of atrial fibrillation in Indigenous Australians. Medical Journal of Australia, 2020, 212, 212-213.	0.8	5
50	Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study. Journal of the American Heart Association, 2020, 9, e014376.	1.6	14
51	AF-SMART eHealth system for atrial fibrillation screening: how can it fit into clinical practice?. Expert Review of Medical Devices, 2020, 17, 375-378.	1.4	1
52	Nurse Led Smartphone Electrographic Monitoring for Atrial Fibrillation after Ischemic Stroke: SPOT-AF. Journal of Stroke, 2020, 22, 387-395.	1.4	14
53	Association between beta-blocker use and obesity in Hong Kong Chinese elders: a post-hoc analysis. , 2020, 26, 27-34.		0
54	Title is missing!. , 2020, 17, e1003146.		0

#	Article	IF	CITATIONS
55	Title is missing!. , 2020, 17, e1003146.		O
56	Title is missing!. , 2020, 17, e1003146.		0
57	Title is missing!. , 2020, 17, e1003146.		0
58	Title is missing!. , 2020, 17, e1003146.		0
59	Atrial Fibrillation Among Indigenous Populations Globally. Heart Lung and Circulation, 2019, 28, S39-S40.	0.2	5
60	Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. International Journal of Cardiology, 2019, 296, 65-70.	0.8	14
61	Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. PLoS Medicine, 2019, 16, e1002903.	3.9	90
62	Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review and meta-analysis. European Journal of Cardiovascular Nursing, 2019, 18, 260-271.	0.4	152
63	Feasibility and acceptability of opportunistic screening to detect atrial fibrillation in Aboriginal adults. Australian and New Zealand Journal of Public Health, 2019, 43, 313-318.	0.8	11
64	Cross-sectional Association Between Blood Pressure Status and Atrial Fibrillation in an Elderly Chinese Population. American Journal of Hypertension, 2019, 32, 777-785.	1.0	11
65	Stroke Risk Stratification: CHA2DS2-VA or CHA2DS2-VASc?. Heart Lung and Circulation, 2019, 28, e103.	0.2	2
66	ECG-based cardiac screening programs: Legal, ethical, and logistical considerations. Heart Rhythm, 2019, 16, 1584-1591.	0.3	23
67	Serum Amyloid A Stimulates Vascular and Renal Dysfunction in Apolipoprotein E-Deficient Mice Fed a Normal Chow Diet. Frontiers in Immunology, 2019, 10, 380.	2.2	13
68	Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease. Annals of Internal Medicine, 2019, 171, 181.	2.0	108
69	Searching for Atrial Fibrillation Poststroke. Circulation, 2019, 140, 1834-1850.	1.6	184
70	Uptake of a primary care atrial fibrillation screening program (AF-SMART): a realist evaluation of implementation in metropolitan and rural general practice. BMC Family Practice, 2019, 20, 170.	2.9	20
71	Opportunistic Electrocardiogram Screening for Atrial Fibrillation to Prevent Stroke. JAMA Cardiology, 2019, 4, 91.	3.0	15
72	eHealth Tools to Provide Structured Assistance for Atrial Fibrillation Screening, Management, and Guidelineâ€Recommended Therapy in Metropolitan General Practice: The AFâ€SMART Study. Journal of the American Heart Association, 2019, 8, e010959.	1.6	40

#	Article	IF	CITATIONS
73	Age-and-sex stratified prevalence of atrial fibrillation in rural Western India: Results of SMART-India, a population-based screening study. International Journal of Cardiology, 2019, 280, 84-88.	0.8	35
74	Reducing Stroke Risk in Atrial Fibrillation: Adherence to Guidelines Has Improved, but Patient Persistence with Anticoagulant Therapy Remains Suboptimal. Korean Circulation Journal, 2019, 49, 883.	0.7	41
75	Contactâ€Free Screening of Atrial Fibrillation by a Smartphone Using Facial Pulsatile Photoplethysmographic Signals. Journal of the American Heart Association, 2018, 7, .	1.6	86
76	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	0.7	95
77	Incidence of postoperative atrial fibrillation recurrence in patients discharged in sinus rhythm after cardiac surgery: a systematic review and meta-analysisâ€. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 504-511.	0.5	68
78	Burden of atrial fibrillation in MÄori and Pacific people in New Zealand: a cohort study. Internal Medicine Journal, 2018, 48, 301-309.	0.5	11
79	Choice of Health Options in Prevention of Cardiovascular Events (CHOICE) Replication Study. Heart Lung and Circulation, 2018, 27, 1406-1414.	0.2	4
80	A2637 Detection rate and treatment gap in new asymptomatic and known atrial fibrillation (AF) in a large screening study in community health centres in China (AF-CATCH). Journal of Hypertension, 2018, 36, e283.	0.3	O
81	Atrial Fibrillation Screen, Management And Guideline Recommended Therapy (AF SMART II) in the rural primary care setting: an implementation study protocol. BMJ Open, 2018, 8, e023130.	0.8	13
82	Identification of new-onset atrial fibrillation after cardiac surgery in Vietnam. A feasibility study of a novel screening strategy in a limited-resource setting: study protocol. BMJ Open, 2018, 8, e020800.	0.8	1
83	Incidence of Atrial Fibrillation in Patients With Recent Ischemic Stroke Versus Matched Controls. Stroke, 2018, 49, 2529-2531.	1.0	6
84	Atrial fibrillation: is there enough evidence to recommend opportunistic or systematic screening?. International Journal of Epidemiology, 2018, 47, 1372-1378.	0.9	8
85	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung and Circulation, 2018, 27, 1209-1266.	0.2	216
86	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Medical Journal of Australia, 2018, 209, 356-362.	0.8	50
87	Major progress in anticoagulant uptake for atrial fibrillation at last: does it translate into stroke prevention?. European Heart Journal, 2018, 39, 2984-2986.	1.0	14
88	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2018, 154, 1121-1201.	0.4	718
89	Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience. Current Medical Research and Opinion, 2017, 33, 1337-1341.	0.9	14
90	Screening for Atrial Fibrillation. Circulation, 2017, 135, 1851-1867.	1.6	453

#	Article	IF	CITATIONS
91	Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications. Heart Rhythm, 2017, 14, 866-874.	0.3	47
92	To Screen or Not to Screen? Examining the Arguments Against Screening for Atrial Fibrillation. Heart Lung and Circulation, 2017, 26, 880-886.	0.2	12
93	Smartphone electrographic monitoring for atrial fibrillation in acute ischemic stroke and transient ischemic attack. International Journal of Stroke, 2017, 12, 786-789.	2.9	20
94	Screening of older patients for atrial fibrillation in general practice: Current evidence and its implications for future practice. European Journal of General Practice, 2017, 23, 246-253.	0.9	15
95	Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nature Reviews Cardiology, 2017, 14, 701-714.	6.1	98
96	Using the †Think Aloud' Technique to Explore Quality of Life Issues During Standard Quality-of-Life Questionnaires in Patients With Atrial Fibrillation. Heart Lung and Circulation, 2017, 26, 150-156.	0.2	13
97	Stroke prevention in atrial fibrillation: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1230-1239.	1.8	346
98	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación CardÃaca y ElectrofisiologÃa (SOLAECE). Europace, 2017, 19, 1589-1623.	0.7	208
99	The role of atrial fibrillation in patients with an embolic stroke of unknown source (ESUS). Thrombosis and Haemostasis, 2017, 117, 1833-1835.	1.8	13
100	Rationale and Design of the Randomized Controlled Trial of Intensive Versus Usual ECG Screening for Atrial Fibrillation in Elderly Chinese by an Automated ECG System in Community Health Centers in Shanghai (AF-CATCH). Cardiovascular Innovations and Applications, 2017, 2, .	0.1	2
101	The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. Global Heart, 2017, 12, 273.	0.9	35
102	"Unreal world―or "real world―data in oral anticoagulant treatment of atrial fibrillation. Thrombosis and Haemostasis, 2016, 116, 587-589.	1.8	52
103	Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ, The, 2016, 355, i5968.	3.0	125
104	AF-SCREEN international collaboration. European Heart Journal, 2016, 37, 3490-3491.	1.0	7
105	Opportunistic screening to detect atrial fibrillation in Aboriginal adults in Australia. BMJ Open, 2016, 6, e013576.	0.8	12
106	Falling cholesterol trend at acute coronary syndrome presentation is strongly related to statin use for secondary prevention. International Journal of Cardiology, 2016, 212, 192-197.	0.8	3
107	Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation. JAMA Cardiology, 2016, 1, 366.	3.0	59
108	Screening for Atrial Fibrillation Using a Smartphone: Is There an App for That?. Journal of the American Heart Association, 2016, 5, .	1.6	33

#	Article	IF	Citations
109	Feasibility of screening for atrial fibrillation in primary care: Just a heartbeat away?. European Journal of Preventive Cardiology, 2016, 23, 1783-1784.	0.8	O
110	Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience. Current Medical Research and Opinion, 2016, 32, 1857-1861.	0.9	27
111	Stroke prevention in atrial fibrillation. Lancet, The, 2016, 388, 806-817.	6.3	329
112	Atrial fibrillation. Nature Reviews Disease Primers, 2016, 2, 16016.	18.1	185
113	Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. Thrombosis and Haemostasis, 2016, 115, 31-39.	1.8	142
114	Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): A feasibility study. European Journal of Preventive Cardiology, 2016, 23, 13-20.	0.8	83
115	Can screening for atrial fibrillation be implemented at scale?. Europace, 2016, 18, 1449-1451.	0.7	6
116	Self-monitoring for atrial fibrillation recurrence in the discharge period post-cardiac surgery using an iPhone electrocardiogram. European Journal of Cardio-thoracic Surgery, 2016, 50, 44-51.	0.6	59
117	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	0.7	121
118	Choice of Health Options In prevention of Cardiovascular Events for people with Atrial Fibrillation (CHOICE-AF): A pilot study. European Journal of Cardiovascular Nursing, 2016, 15, 39-46.	0.4	8
119	Pleiotropic, heart rateâ€independent cardioprotection by ivabradine. British Journal of Pharmacology, 2015, 172, 4380-4390.	2.7	60
120	Is risk-benefit of warfarin for atrial fibrillation with heart failure determined by heart failure severity?. Thrombosis and Haemostasis, 2015, 114 , $1-3$.	1.8	27
121	Clinical Exercise Stress Testing in Adults (2014). Heart Lung and Circulation, 2015, 24, 831-837.	0.2	8
122	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. European Heart Journal, 2015, 36, 653-656.	1.0	58
123	Serum Amyloid A Receptor Blockade and Incorporation into High-Density Lipoprotein Modulates Its Pro-Inflammatory and Pro-Thrombotic Activities on Vascular Endothelial Cells. International Journal of Molecular Sciences, 2015, 16, 11101-11124.	1.8	22
124	The mobile revolutionâ€"using smartphone apps to prevent cardiovascular disease. Nature Reviews Cardiology, 2015, 12, 350-360.	6.1	182
125	Asymptomatic Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2015, 314, 1911.	3.8	45
126	Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. International Journal of Clinical Pharmacy, 2015, 37, 1111-1120.	1.0	63

#	Article	IF	Citations
127	Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013. Heart, 2015, 101, 1748-1754.	1.2	55
128	Identifying postoperative atrial fibrillation in cardiac surgical patients posthospital discharge, using iPhone ECG: a study protocol. BMJ Open, 2015, 5, e006849-e006849.	0.8	7
129	Statin Therapy and Cognition in Older People: What is the Evidence?. Current Clinical Pharmacology, 2015, 10, 185-193.	0.2	10
130	Preâ€treatment with the synthetic antioxidant Tâ€butyl bisphenol protects cerebral tissues from experimental ischemia reperfusion injury. Journal of Neurochemistry, 2014, 130, 733-747.	2.1	15
131	Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. New England Journal of Medicine, 2014, 371, 1091-1099.	13.9	399
132	Isolated hypertrophy of the basal ventricular septum: Characteristics of patients with and without outflow tract obstruction. International Journal of Cardiology, 2014, 173, 487-493.	0.8	30
133	Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. Thrombosis and Haemostasis, 2014, 111, 1167-1176.	1.8	407
134	Adverse prognosis of incidentally detected ambulatory atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 276-286.	1.8	120
135	A simple screening tool for assessment of nutritional status in cardiac patients. British Journal of Cardiac Nursing, 2014, 9, 508-512.	0.0	2
136	Pharmacy-based screening for atrial fibrillation in high-risk Maori and Pacific populations. New Zealand Medical Journal, 2014, 127, 128-31.	0.5	3
137	iPhone ECG application for community screening to detect silent atrial fibrillation: A novel technology to prevent stroke. International Journal of Cardiology, 2013, 165, 193-194.	0.8	293
138	Cardiac troponin-T and the prediction of acute and long-term mortality after acute pulmonary embolism. International Journal of Cardiology, 2013, 165, 126-133.	0.8	30
139	Screening for atrial fibrillation above age 65 detects an asymptomatic subset at high risk of stroke. International Journal of Cardiology, 2013, 164, 371-372.	0.8	24
140	Fog on the Crystal Ball? Missing Atrial Fibrillation in Forecasting the Future of Stroke. Stroke, 2013, 44, e136.	1.0	1
141	Serum amyloid <scp>A</scp> stimulates cultured endothelial cells to migrate and proliferate: inhibition by the multikinase inhibitor <scp>BIBF</scp> 1120. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 662-670.	0.9	16
142	Medical graduates becoming rural doctors: rural background versus extended rural placement. Medical Journal of Australia, 2013, 199, 779-782.	0.8	58
143	Screening to identify unknown atrial fibrillation. Thrombosis and Haemostasis, 2013, 110, 213-222.	1.8	268
144	Screening Education And Recognition in Community pHarmacies of Atrial Fibrillation to prevent stroke in an ambulant population aged ≥65â€years (SEARCH-AF stroke prevention study): a cross-sectional study protocol. BMJ Open, 2012, 2, e001355.	0.8	17

#	Article	IF	CITATIONS
145	Lifestyle risk reduction interventions in atrial fibrillation: a systematic review. European Journal of Preventive Cardiology, 2012, 19, 1091-1100.	0.8	17
146	Changing the lexicon of â€~Cardiac Rehabilitation': a progressive step. European Journal of Preventive Cardiology, 2012, 19, 167-168.	0.8	0
147	Participating in cardiac rehabilitation: a systematic review and meta-synthesis of qualitative data. European Journal of Preventive Cardiology, 2012, 19, 494-503.	0.8	250
148	Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scandinavian Journal of Rheumatology, 2011, 40, 411-421.	0.6	41
149	Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. International Journal of Cardiology, 2011, 146, 408-414.	0.8	80
150	Response to Letter by Stöllberger et al Regarding Article, "Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation― Stroke, 2011, 42, .	1.0	0
151	The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein. Free Radical Biology and Medicine, 2011, 51, 1390-1398.	1.3	34
152	Beta-Blocker Dose Up-Titration or Addition of Ivabradine in Stable Angina: More is Not Necessarily Better. Cardiovascular Drugs and Therapy, 2011, 25, 501-502.	1.3	4
153	Letter by Neubeck et al Regarding Article, "lmpact of Cardiac Rehabilitation on Mortality and Cardiovascular Events After Percutaneous Coronary Intervention in the Community― Circulation, 2011, 124, e572; author reply e573.	1.6	1
154	Nurse-Led Telephone Interventions for People with Cardiac Disease: The Importance of the Multi-Disciplinary Approach. European Journal of Cardiovascular Nursing, 2011, 10, 70-71.	0.4	2
155	Planning Locally Relevant Internet Programs for Secondary Prevention of Cardiovascular Disease. European Journal of Cardiovascular Nursing, 2011, 10, 213-220.	0.4	20
156	Unusual Features of Apical Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2010, 105, 879-883.	0.7	19
157	Increased tissue factor activity in monocytes from obese young adults. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 1049-1054.	0.9	31
158	Acute coronary syndromes: consensus recommendations for translating knowledge into action. Medical Journal of Australia, 2010, 193, 550-553.	0.8	0
159	Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation. Stroke, 2010, 41, 2705-2713.	1.0	70
160	Incidence and determinants of myocardial infarction following percutaneous coronary interventions according to the revised Joint Task Force definition of troponin T elevation. International Journal of Cardiology, 2010, 140, 66-72.	0.8	22
161	Lack of widespread inflammation after contemporary PCI. International Journal of Cardiology, 2010, 140, 82-87.	0.8	4
162	Impact of sleep disordered breathing severity on hemodynamics, autonomic balance and cardiopulmonary functional status in chronic heart failure. International Journal of Cardiology, 2010, 141, 227-235.	0.8	8

#	Article	IF	Citations
163	Impact of medical consultation frequency on modifiable risk factors and medications at 12 months after acute coronary syndrome in the CHOICE randomised controlled trial. International Journal of Cardiology, 2010, 145, 481-486.	0.8	16
164	Post acute management of coronary disease: Moving forward. International Journal of Cardiology, 2010, 145, 597.	0.8	0
165	Acute coronary syndromes: consensus recommendations for translating knowledge into action. Medical Journal of Australia, 2009, 191, 334-338.	0.8	29
166	Supraventricular tachycardia. Medical Journal of Australia, 2009, 190, 255-260.	0.8	34
167	Pleiotropic Roles of \$100A12 in Coronary Atherosclerotic Plaque Formation and Rupture. Journal of Immunology, 2009, 183, 593-603.	0.4	68
168	A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Report, 2009, 14, 187-196.	1.4	65
169	Choice of secondary prevention improves risk factors after acute coronary syndrome: 1-year follow-up of the CHOICE (Choice of Health Options In prevention of Cardiovascular Events) randomised controlled trial. Heart, 2009, 95, 468-475.	1.2	115
170	Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 281-289.	3.1	226
171	Sleep disordered breathing in chronic heart failure. Heart Failure Reviews, 2009, 14, 89-99.	1.7	19
172	Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes. Atherosclerosis, 2009, 202, 596-604.	0.4	52
173	Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis, 2009, 207, 374-383.	0.4	113
174	Delirium cordis: can we predict the onset of atrial fibrillation?. Lancet, The, 2009, 373, 698-700.	6.3	6
175	Prospective evaluation of the impact of diabetes and left ventricular hypertrophy on the relationship between ischemia and transient ischemic dilation of the left ventricle on single-day adenosine Tc-99m myocardial perfusion imaging. Journal of Nuclear Cardiology, 2008, 15, 638-643.	1.4	18
176	The CHOICE (Choice of Health Options In prevention of Cardiovascular Events) replication trial: study protocol. BMC Cardiovascular Disorders, 2008, 8, 25.	0.7	12
177	Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Annals of Medicine, 2008, 40, 428-436.	1.5	120
178	Differences in management and outcome of ischemic and non-ischemic cardiomyopathy. International Journal of Cardiology, 2008, 129, 198-204.	0.8	34
179	Low utilisation of cardiovascular risk reducing therapy in patients with acute coronary syndromes and non-obstructive coronary artery disease. International Journal of Cardiology, 2008, 129, 394-398.	0.8	23
180	Polymorphonuclear leukocyte phagocytic function increases in plasminogen knockout mice. Thrombosis Research, 2008, 122, 674-682.	0.8	7

#	Article	IF	CITATIONS
181	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	6.3	934
182	Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet, The, 2008, 372, 817-821.	6.3	694
183	The late open artery hypothesis: the case and the artery remain closed. European Heart Journal, 2008, 30, 129-130.	1.0	O
184	Letter by Chung et al Regarding Article, "N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study― Circulation, 2008, 117, e5; author reply e6.	1.6	0
185	Patient-Centered Modular Secondary Prevention Following Acute Coronary Syndrome. Journal of Cardiopulmonary Rehabilitation and Prevention, 2008, 28, 107-115.	1.2	35
186	Medical schools can cooperate: a new joint venture to provide medical education in the Northern Rivers region of New South Wales. Medical Journal of Australia, 2008, 188, 179-181.	0.8	1
187	Serum Amyloid A Induces Monocyte Tissue Factor. Journal of Immunology, 2007, 178, 1852-1860.	0.4	104
188	Autonomic Abnormalities in Congestive Heart Failure Patients With Sleep-Disordered Breathing. Journal of Cardiac Failure, 2007, 13, 395-400.	0.7	5
189	High riskâ€factor level and low riskâ€factor knowledge in patients not accessing cardiac rehabilitation after acute coronary syndrome. Medical Journal of Australia, 2007, 186, 21-25.	0.8	68
190	Atrial fibrillation. Medical Journal of Australia, 2007, 186, 197-202.	0.8	30
191	Guidelines for submitting adverse event reports for publication. Pharmacoepidemiology and Drug Safety, 2007, 16, 581-587.	0.9	73
192	Influence of history of heart failure on diagnostic performance and utility of B-type natriuretic peptide testing for acute dyspnea in the emergency department. American Heart Journal, 2006, 152, 949-955.	1.2	26
193	C-reactive protein contributes to the hypercoagulable state in coronary artery disease. Journal of Thrombosis and Haemostasis, 2006, 4, 98-106.	1.9	24
194	Development and testing of innovative patient resources for the management of coronary heart disease (CHD): a descriptive study. BMC Health Services Research, 2006, 6, 95.	0.9	19
195	Lumen Loss in the First Year in Saphenous Vein Grafts Is Predominantly a Result of Negative Remodeling of the Whole Vessel Rather Than a Result of Changes in Wall Thickness. Circulation, 2006, 114, I-435-I-440.	1.6	45
196	Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Internal Medicine Journal, 2005, 35, 331-335.	0.5	77
197	Costâ€effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Medical Journal of Australia, 2005, 183, 450-455.	0.8	92
198	Hypertriglyceridaemia is associated with early non-patency of coronary bypass grafts. Heart, 2005, 92, 536-538.	1.2	1

#	Article	IF	CITATIONS
199	Coronary Artery Stenoses: Detection with Calcium Scoring, CT Angiography, and Both Methods Combined. Radiology, 2005, 235, 415-422.	3.6	63
200	Atrial Fibrillation. Primary Care - Clinics in Office Practice, 2005, 32, 1083-1107.	0.7	3
201	Emergency department assessment of patients with acute chest pain: myocardial perfusion imaging, blood tests, or both?. Journal of Nuclear Cardiology, 2004, 11, 87-89.	1.4	2
202	The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. Journal of the American College of Cardiology, 2004, 44, 57-62.	1.2	102
203	Effects of angiotensin-converting enzyme inhibition on transient ischemia. Journal of the American College of Cardiology, 2003, 42, 2049-2059.	1.2	42
204	Soluble CD40 Ligand in Acute Coronary Syndromes. New England Journal of Medicine, 2003, 348, 2575-2577.	13.9	29
205	P1704 Polymorphonuclear leucocytes (PMNs) phagocytosis function is enhanced in plasminogen knockout mice. European Heart Journal, 2003, 24, 322.	1.0	0
206	Plasma Vascular Endothelial Growth Factor (VEGF) Levels After Intramuscular and Intramyocardial Gene Transfer of VEGF-1 Plasmid DNA. Human Gene Therapy, 2002, 13, 1595-1603.	1.4	35
207	Therapeutic Angiogenesis for Coronary Artery Disease. Annals of Internal Medicine, 2002, 136, 54.	2.0	211
208	Influence of Plasminogen Deficiency on the Contribution of Polymorphonuclear Leucocytes to Fibrin/ogenolysis. Thrombosis and Haemostasis, 2002, 88, 805-810.	1.8	22
209	Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes. American Journal of Cardiology, 2002, 89, 1167-1170.	0.7	8
210	Therapeutic Angiogenesis for Ischemic Cardiovascular Disease. Journal of Molecular and Cellular Cardiology, 2001, 33, 379-393.	0.9	174
211	Cytomegalovirus Seropositivity and C-Reactive Protein Have Independent and Combined Predictive Value for Mortality in Patients With Angiographically Demonstrated Coronary Artery Disease. Circulation, 2001, 104, E20-1.	1.6	3
212	Tremor-Induced ECG Artifact Mimicking Ventricular Tachycardia. Circulation, 2001, 103, E112-2.	1.6	3
213	Interferon- \hat{l}^3 and Lipopolysaccharide Potentiate Monocyte Tissue Factor Induction by C-Reactive Protein. Circulation, 2000, 101, 1785-1791.	1.6	159
214	Acute Reaction to Dipyridamole during Myocardial Scintigraphy. New England Journal of Medicine, 1999, 340, 394-394.	13.9	12
215	Direct transmission of electrocardiograms to a mobile phone for management of a patient with acute myocardial infarction. Journal of Telemedicine and Telecare, 1999, 5, 67-69.	1.4	19
216	Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. American Journal of Cardiology, 1999, 83, 1120-1124.	0.7	30

#	Article	IF	Citations
217	Vascular risk factors correlate to the extent as well as the severity of coronary atherosclerosis. Coronary Artery Disease, 1999, 10, 449-454.	0.3	14
218	Triggers of daily life ischaemia. Heart, 1998, 80, 489-492.	1.2	9
219	International, Randomized, Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable Angina. Circulation, 1998, 97, 2386-2395.	1.6	377
220	Usefulness of laboratory mental stress test in patients with stable coronary artery disease. Clinical Cardiology, 1997, 20, 367-371.	0.7	8
221	Electrocardiographic measurement of infarct size after thrombolytic therapy. Journal of the American College of Cardiology, 1996, 27, 617-624.	1.2	60
222	Reperfusion in acute inferior myocardial infarction: Could tailored therapy be based on precordial ST depression?. American Heart Journal, 1996, 131, 1240-1247.	1.2	8
223	Correlation between post-ejection shortening and improvement in regional wall motion after revascularization in patients with coronary artery disease. International Journal of Cardiology, 1996, 54, 61-67.	0.8	42
224	Electrocardiographic identification of the infarct-related artery in acute inferior myocardial infarction. International Journal of Cardiology, 1996, 54, 5-11.	0.8	17
225	Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. American Journal of Cardiology, 1996, 78, 516-519.	0.7	58
226	Significance of precordial T-wave inversion in inferior wall acute myocardial infarction. American Journal of Cardiology, 1995, 75, 81-83.	0.7	6
227	Precordial ST change and site of the infarct-related lesion in right coronary artery-related inferior wall acute myocardial infarction. American Journal of Cardiology, 1995, 75, 942-943.	0.7	4
228	Australia. Global Health Promotion, 1995, 2, 36-42.	0.8	1
229	Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: Potential role of rebound ischemia during the nitrate-free period. Journal of the American College of Cardiology, 1995, 25, 349-355.	1.2	31
230	Relation Between Ischemia Time, Infarct Size, and Left Ventricular Function in Humans. Circulation, 1995, 92, 710-719.	1.6	76
231	Carotid Intima-Media Thickness Is Only Weakly Correlated With the Extent and Severity of Coronary Artery Disease. Circulation, 1995, 92, 2127-2134.	1.6	324
232	Implications of ST changes in reperfusion management of acute inferior myocardial infarction. European Heart Journal, 1994, 15, 1385-1390.	1.0	7
233	Usefulness of continuous ST monitoring in inferior wall acute myocardial infarction for describing the relation between precordial ST depression and inferior ST elevation. American Journal of Cardiology, 1993, 72, 532-537.	0.7	19
234	Mechanism and significance of precordial ST-segment depression during inferior wall acute myocardial infarction associated with severe narrowing of the dominant right coronary artery. American Journal of Cardiology, 1993, 71, 1025-1030.	0.7	35

#	Article	IF	Citations
235	Derivation and validation of a new angiographic score of right coronary artery perfusion. European Heart Journal, 1993, 14, 469-473.	1.0	7
236	Regional thallium uptake in irreversible defects Circulation, 1992, 86, 1043-1044.	1.6	6
237	Efficacy, safety and duration of nitrate-free interval to prevent tolerance to transdermal nitroglycerin in effort angina. European Heart Journal, 1992, 13, 671-678.	1.0	18
238	Prognostic significance of a predischarge exercise test in risk stratification after unstable angina pectoris. Journal of the American College of Cardiology, 1991, 18, 677-683.	1.2	83
239	Detection of myocardial viability in stunned or hibernating myocardium by delayed emptying on radionuclide ventriculography. American Journal of Cardiology, 1991, 67, 529-532.	0.7	11
240	Comparison of exercise stress testing with ambulatory electrocardiographic monitoring in the detection of myocardial ischemia after unstable angina pectoris. American Journal of Cardiology, 1991, 67, 89-91.	0.7	14
241	The unstable ST segment early after thrombolysis for acute infarction and its usefulness as a marker of recurrent coronary occlusion. American Journal of Cardiology, 1991, 67, 109-115.	0.7	103
242	Detection of "silent―ischemia during induction of anesthesia for coronary bypass surgery by real-time ST monitoring. Coronary Artery Disease, 1990, 1, 567-572.	0.3	2
243	ST monitoring for myocardial ischemia during and after coronary angioplasty. American Journal of Cardiology, 1990, 66, 389-393.	0.7	25
244	Clinical significance of silent ischemia in unstable angina pectoris. American Journal of Cardiology, 1990, 65, 1313-1316.	0.7	47
245	A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. American Heart Journal, 1990, 119, 1262-1267.	1.2	246
246	Effects of diltiazem and long-term beta1-adrenergic blockade on hemodynamics and blood flow during excersise in ptients with stable angina pectoris. Journal of the American College of Cardiology, 1990, 15, 184-188.	1.2	2
247	Factors influencing the time from onset of chest pain to arrival at hospital. Medical Journal of Australia, 1989, 150, 6-10.	0.8	71
248	Effects of nisoldipine on systemic and leg blood flow, oxygen transport and metabolism, and hemodynamics during exercise in effort angina pectoris. American Journal of Cardiology, 1989, 63, 802-806.	0.7	5
249	Evaluation of a microprocessor-controlled sphygmomanometer for recording blood pressure during exercise. American Journal of Cardiology, 1989, 64, 806-808.	0.7	2
250	Risk of adverse outcome in patients admitted to the coronary care unit with suspected unstable angina pectoris. American Journal of Cardiology, 1989, 64, 845-848.	0.7	26
251	ST-segment changes during transmural myocardial ischemia in chronic left bundle branch block. American Journal of Cardiology, 1989, 64, 1216-1217.	0.7	14
252	Normalised radionuclide measures of left ventricular diastolic function. European Journal of Nuclear Medicine and Molecular Imaging, 1989, 15, 123-7.	2,2	21

#	Article	IF	CITATIONS
253	Comparison of the Effects of Nifedipine and Nitroglycerin on Hemodynamic Determinants of Myocardial Oxygen Consumption and Supply During Exertional Angina. Journal of Cardiovascular Pharmacology, 1989, 13, 361-369.	0.8	8
254	Regional distribution of cardiac output at rest and during exercise in patients with exertional angina pectoris before and after nifedipine therapy. Journal of the American College of Cardiology, 1988, 11, 837-842.	1.2	10
255	Comparison of carvedilol and atenolol for angina pectoris. American Journal of Cardiology, 1987, 60, 499-502.	0.7	26
256	Validation of a real-time electrocardiographic monitor for detection of myocardial ischemia secondary to coronary artery disease. American Journal of Cardiology, 1987, 60, 525-527.	0.7	34
257	Supraventricular tachycardia. Mechanisms and therapy. Archives of Internal Medicine, 1987, 147, 1706-1716.	4.3	0
258	Prediction of multivessel coronary artery disease and prognosis early after acute myocardial infarction by exercise electrocardiography and thallium-201 myocardial perfusion scanning. American Journal of Cardiology, 1986, 58, 423-427.	0.7	74
259	Late follow-up (41 to 102 months) of medically treated patients with coronary artery spasm and minor atherosclerotic coronary obstructions. American Journal of Cardiology, 1986, 57, 1261-1263.	0.7	26
260	Influence of coronary collateral blood flow on the development of exertional ischemia and Q wave infarction in patients with severe single-vessel disease Circulation, 1985, 71, 681-686.	1.6	57
261	Different susceptibility to myocardial ischemia provoked by hyperventilation and cold pressor test in exertional and variant angina pectoris. American Journal of Cardiology, 1985, 56, 18-22.	0.7	58
262	Ergonovine-induced myocardial ischemia: no role for serotonergic receptors?. Circulation, 1984, 70, 178-183.	1.6	120
263	Myocardial ischemia during ergonovine testing: different susceptibility to coronary vasoconstriction in patients with exertional and variant angina Circulation, 1984, 69, 690-695.	1.6	40
264	Impairment of myocardial perfusion and function during painless myocardial ischemia. Journal of the American College of Cardiology, 1983, 1, 924-930.	1.2	299
265	Pathophysiology of coronary artery spasm Circulation, 1982, 66, 705-709.	1.6	79
266	Verapamil in stable effort angina: Effects on left ventricular function evaluated with exercise radionuclide ventriculography. American Journal of Cardiology, 1982, 49, 425-430.	0.7	61
267	Long-term follow-up of verapamil and nitrate treatment for coronary artery spasm. American Journal of Cardiology, 1982, 50, 711-715.	0.7	58
268	Localization of coronary artery disease with exercise electrocardiography: correlation with thallium-201 myocardial perfusion scanning. American Journal of Cardiology, 1981, 48, 837-843.	0.7	76
269	Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clinical Pharmacology and Therapeutics, 1981, 30, 644-652.	2.3	117
270	Coronary artery spasm during exercise: treatment with verapamil Circulation, 1981, 64, 68-75.	1.6	36

#	Article	IF	CITATIONS
271	Exercise-induced ST-segment elevation in leads V1 or aVL. A predictor of anterior myocardial ischemia and left anterior descending coronary artery disease Circulation, 1981, 63, 1357-1363.	1.6	51
272	Coronary Artery Spasm*. Australian and New Zealand Journal of Medicine, 1980, 10, 69-72.	0.5	5
273	The Value of Exercise Electrocardiography and Exercise Thalliumâ€201 Myocardial Perfusion Scanning in Determining the Presence of Single Vessel Coronary Artery Obstruction. Australian and New Zealand Journal of Medicine, 1980, 10, 520-525.	0.5	3
274	Coronary Artery Spasm: Use of Ergonovine in Diagnosis *. Australian and New Zealand Journal of Medicine, 1980, 10, 6-11.	0.5	13
275	Serial Thalliumâ€201 Myocardial Perfusion Scanning in Acute Myocardial Infarction*. Australian and New Zealand Journal of Medicine, 1980, 10, 629-635.	0.5	2
276	Noninvasive prediction of multivessel disease after myocardial infarction Circulation, 1980, 62, 726-734.	1.6	69
277	STUDENT EVALUATION OF THE SYDNEY UNIVERSITY MEDICAL COURSE. Medical Journal of Australia, 1973, 1, 179-184.	0.8	2
278	Implantable cardiac monitors compared with conventional methods for the detection of atrial high-rate episodes in individuals with embolic stroke of undetermined source. The Cochrane Library, 0, , .	1.5	1